No Data
No Data
Jiangsu Jibeier Pharmaceutical Co., Ltd. (Stock Code: 688566.SH) announced Q1 2024 equity distribution of CNY 0.26 per share on July 9, with the ownership registration.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (SH: 688566) has issued an announcement on the implementation of equity distribution for the first quarter of 2024. The profit distribution this time will be based on...
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) plans to distribute 2.6 yuan per 10 shares in the first quarter.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) announced that the company plans to distribute equity shares as dividends in the first quarter of 2024...
Gibbel (688566.SH): The application for a fixed increase was reviewed and approved by the Shanghai Stock Exchange
GLONGHUI, May 9, 丨 Jiber (688566.SH) announced that the company received an audit opinion from the Shanghai Stock Exchange on the company's application to issue A shares to specific targets using a simple procedure in 2023: According to the “Shanghai Stock Exchange Listed Company Securities Issuance and Listing Review Rules”, Jiangsu Gibel Pharmaceutical Co., Ltd. met the issuance conditions, listing conditions and information disclosure requirements by issuing shares to specific targets through simple procedures.
Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerni
Gibbel (688566.SH) released 2023 annual results, with net profit of 219 million yuan, an increase of 41.65% over the previous year
Gibbel (688566.SH) released its 2023 annual report. The company achieved operating income of 8.6 during the reporting period...
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) 11% Gain Last Week Benefited Both Private Companies Who Own 37% as Well as Insiders
Key Insights Jiangsu Jibeier Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 2 investors hav
No Data